Evidence map›Paper›PMID 28710250›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2017

Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine.

Kaitlyn Morse, Yoshifumi Kimizuka, Megan P K Chan, Mai Shibata, Yusuke Shimaoka, Shu Takeuchi, Benjamin Forbes, Christopher Nirschl, Binghao Li, Yang Zeng and 14 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. A pilot clinical trial of a near-infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Trial
  2. Article
  3. Emerging adjuvants for intradermal vaccination.International journal of pharmaceutics · 2023
    Review
  4. Photobiomodulation and nitric oxide signaling.Nitric oxide : biology and chemistry · 2023
    Review
  5. Article
  6. Dual near-infrared II laser modulates the cellular redox state of T cells and augments the efficacy of cancer immunotherapy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  7. Near-infrared II photobiomodulation augments nitric oxide bioavailability via phosphorylation of endothelial nitric oxide synthase.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  8. Article
  9. Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Laser adjuvant for vaccination.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Kaitlyn MorseVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.ORCID 0000-0002-3077-2832
Yoshifumi KimizukaVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Megan P K ChanVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Mai ShibataVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Yusuke ShimaokaVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Shu TakeuchiVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.ORCID 0000-0002-6274-9485
Benjamin ForbesVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Christopher NirschlDepartment of Dermatology, Harvard Skin Disease Research Center, Brigham and Women's Hospital, Boston, MA 02115.ORCID 0000-0002-7333-2757
Binghao LiVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Yang ZengVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Roderick T BronsonDepartment of Pathology, Harvard Medical School, Boston, MA 02115.
Wataru KatagiriGraduate School of Fundamental Science and Technology, Keio University, Yokohama, Kanagawa 223-8522, Japan; and.
Ayako ShigetaVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Ruxandra F SîrbulescuVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.ORCID 0000-0001-7905-1713
Huabiao ChenVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Rhea Y Y TanVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.ORCID 0000-0002-4056-9205
Kosuke TsukadaGraduate School of Fundamental Science and Technology, Keio University, Yokohama, Kanagawa 223-8522, Japan; and.
Timothy BraunsVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.ORCID 0000-0002-2161-551X
Jeffrey GelfandVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.ORCID 0000-0002-4118-5676
Ann SluderVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Joseph J LocascioAlzheimer's Disease Research Center, Department of Neurology and Psychiatry, Massachusetts General Hospital, Boston, MA 02114.ORCID 0000-0003-3439-1209
Mark C PoznanskyVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129.
Niroshana AnandasabapathyDepartment of Dermatology, Harvard Skin Disease Research Center, Brigham and Women's Hospital, Boston, MA 02115.ORCID 0000-0002-0473-8358
Satoshi KashiwagiVaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129; skashiwagi@mgh.harvard.edu.

Funding

Peripheral mechanisms of homeostasis and tolerance through skin dendritic cellsR01AR070234 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANANDASABAPATHY, NIROSHANA · 2016 to 2020
$2.6M
Near-infrared laser to replace chemical vaccine adjuvantR01AI105131 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KASHIWAGI, SATOSHI · 2013 to 2016
$1.7M
Development of small near-infrared laser system capable of improving immune responses to vaccines (laser-based adjuvant)R42AI114012 · NIAID · VERALASE, LLC · PI BEAN, DAVID · 2016 to 2017
$1.4M
Development of small near-infrared laser system capable of improving immune respoR41AI114012 · NIAID · SEMINEX CORPORATION · PI CALLAHAN, JOHN JAMES · 2014 to 2014
$147k
NIAID NIH HHS R01 AI105131NIAID NIH HHS R41 AI114012NIAID NIH HHS R42 AI114012NIAMS NIH HHS R01 AR070234
6 · The paper itself

Abstract

Brief exposure of skin to near-infrared (NIR) laser light has been shown to augment the immune response to intradermal vaccination and thus act as an immunologic adjuvant. Although evidence indicates that the NIR laser adjuvant has the capacity to activate innate subsets including dendritic cells (DCs) in skin as conventional adjuvants do, the precise immunological mechanism by which the NIR laser adjuvant acts is largely unknown. In this study we sought to identify the cellular target of the NIR laser adjuvant by using an established mouse model of intradermal influenza vaccination and examining the alteration of responses resulting from genetic ablation of specific DC populations. We found that a continuous wave (CW) NIR laser adjuvant broadly modulates migratory DC (migDC) populations, specifically increasing and activating the Lang

Indexed as

Infrared RaysLasersAdjuvants, ImmunologicAnimalsAntigens, SurfaceCell MovementDendritic CellsInfluenza VaccinesInjections, IntradermalLectins, C-TypeMannose-Binding LectinsMiceReceptors, CCR2SkinVaccinationAdjuvants, ImmunologicAntigens, SurfaceCcr2 protein, mouseCd207 protein, mouseInfluenza VaccinesLectins, C-TypeMannose-Binding LectinsReceptors, CCR2

Identifiers

PMID28710250
PMCPMC5555148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.